Greenwich LifeSciences (GLSI) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed SIGA Technologies (SIGA) over the past year, gaining 37.0% versus a loss of 61.4%. Over five years, SIGA leads with a -54.1% price change compared with -59.5% for GLSI. SIGA Technologies is the larger company by market cap ($237.8 million vs $215.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | SIGA |
|---|---|---|
| Share price | $14.65 | $3.31 |
| Market cap | $215.04M | $237.82M |
| 1-day change | -4.81% | +1.53% |
| YTD return | -26.75% | -46.64% |
| 1-year return | +37.04% | -61.37% |
| 5-year return | -59.46% | -54.15% |
| Forward P/E | — | 3.06 |
| EPS (TTM) | $-1.53 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $8.55 |
| 52-week low | $7.78 | $2.83 |
| Distance from 52-week high | -57.04% | -61.29% |
| Analyst consensus | none | none |
| Avg. price target upside | +289.08% | — |
| Average volume | 138.72K | 726.50K |
| Shares outstanding | 14.68M | 71.85M |
| Employees | — | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed SIGA by 98.4 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
GLSI vs SIGA FAQ
Which is bigger, Greenwich LifeSciences or SIGA Technologies?
SIGA Technologies (SIGA) is larger, with a market capitalization of $237.82M compared with $215.04M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, GLSI or SIGA?
GLSI returned +37.04% over the past 12 months, compared with -61.37% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and SIGA Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.